Characterization of hepatitis C virus core-specific immune responses primed in rhesus macaques by a nonclassical ISCOM vaccine

Journal of Immunology

Volumn 166, Issue 5, 2001, Pages 3589-3598

  Polakos, N K ^a   Drane, D ^a   Cox, J ^a   Ng, P ^a   Selby, M J ^a   Chien, D ^a   O'Hagan, D T ^a   Houghton, M ^a   Paliard, X ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CORE ISCOM VACCINE; CORE PROTEIN; ISCOM; UNCLASSIFIED DRUG; VACCINE;

ANIMAL CELL; ANTIBODY DETECTION; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; DRUG SCREENING; FEMALE; GENOTYPE; HEPATITIS C; HUMORAL IMMUNITY; IMMUNE RESPONSE; INFECTION CONTROL; MOUSE; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; T LYMPHOCYTE; VACCINATION;

EID: 0035284757     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.166.5.3589     Document Type: Article

References (63)

1. The past incidence of hepatitis C virus infection: Implications for the future burden of chronic liver disease in the United States
2. The scientific challenge of hepatitis C
3. Randomised trial of interferon α2b plus ribavirin for 48 or for 24 wk vs interferon α2b plus placebo for 48 wk for treatment of chronic infection with hepatitis C virus: International Hepatitis Interventional Therapy Group (IHIT)
4. Interferon α-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C: Hepatitis Interventional Therapy Group
5. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response
6. Analysis of a successful immune response against hepatitis C virus
7. Analysis of successful immune responses in persons infected with hepatitis C virus
8. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies
9. Pathogenesis, diagnosis and management of hepatitis C
10. Hepatitis C virus (HCV) genotype, tissue HCV antigens, hepatocellular expression of HLA-A,B,C, and intercellular adhesion-1 molecules: Clues to pathogenesis of hepatocellular damage and response to interferon treatment in patients with chronic hepatitis C
11. T-cell-mediated autologous hepatocytotoxicity in patients with chronic hepatitis C virus infection
12. Liver cell apoptosis in chronic hepatitis C correlates with histological but not biochemical activity or serum HCV-RNA levels
13. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy
14. The role of hepatitis C virus-specific cytotoxic T lymphocytes in chronic hepatitis C
15. Intrahepatic hepatitis C virus-specific cytotoxic T lymphocyte activity and response to interferon α therapy in chronic hepatitis C
16. Properties of the hepatitis C virus core protein: A structural protein that modulates cellular processes
17. Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses
18. + cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs
19. + T cell responses by oral or parenteral immunization with ISCOMS
20. Mamu-1: A novel primate MHC class 1 B-related locus with unusually low variability
21. Evaluation of hepatitis C virus glycoprotein E2 for vaccine design: An endoplasmic reticulum-retained recombinant protein is superior to secreted recombinant protein and DNA-based vaccine candidates
22. Studies on experimental adjuvanted influenza vaccines: Comparison of immune stimulating complexes (Iscoms) and oil-in-water vaccines
23. MF59: Design and evaluation of a safe and potent adjuvant for human vaccines
24. Genetic organization and diversity of the hepatitis C virus
25. + cytotoxic T cells after administration of a virus-like particle vaccine in rhesus macaques
26. Isolation and characterization of human papillomavirus type 6-specific T cells infiltrating genital warts
27. Quantification of the number of cytotoxic T cells specific for an immuno-dominant HCV-specific CTL epitope primed by DNA immunization
28. Diagnosis of hepatitis C virus (HCV) infection using an immunodominant chimeric polyprotein to capture circulating antibodies: Reevaluation of the role of HCV in liver disease
29. Binding of hepatitis C virus to CD81
30. Vaccination of chimpanzees against infection by the hepatitis C virus
31. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome
32. + T-cell response in acute hepatitis C
33. Genetic heterogeneity of hepatitis C virus: Quasispecies and genotypes
34. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: Quasispecies nature of HCV genome distribution
35. Sequence analysis of the core gene of 14 hepatitis C virus genotypes
36. Immune selection and genetic sequence variation in core and envelope regions of hepatitis C virus
37. Persistent hepatitis C virus infection in a chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant
38. Hepatitis C virus variants circumventing cytotoxic T lymphocyte activity as a mechanism of chronicity
39. Antigen recognition by class 1-restricted T lymphocytes
40. Mechanisms of MHC class 1-restricted antigen processing
41. Heterologous protection against influenza by injection of DNA encoding a viral protein
42. Capture and processing of exogenous antigens for presentation on MHC molecules
43. Kinetics, localization and cytokine profile of T cell responses to immune stimulating complexes (iscoms) containing human influenza virus envelope glycoproteins
44. + T cells in peripheral blood and liver using peptide-MHC tetramers
45. T cell memory
46. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C
47. Adjuvants: A classification and review of their modes of action
48. Augmentation of human influenza A virus-specific cytotoxic T lymphocyte memory by influenza vaccine and adjuvanted carriers (ISCOMS)
49. Priming in vivo and quantification in vitro of class I MHC-restricted cytotoxic T cells to human papilloma virus type 11 early proteins (E6 and E7) using immunostimulating complexes (ISCOMs)
50. Comparison of immunity generated by nucleic acid-, MF59-, and ISCOM-formulated human immunodeficiency virus type 1 vaccines in rhesus macaques: Evidence for viral clearance
51. The major Epstein-Barr virus (EBV) envelope glycoprotein gp340 when incorporated into iscoms primes cytotoxic T-cell responses directed against EBV lymphoblastoid cell lines
52. Induction of virus-specific immunity by iscoms
53. Pinocytosis and phagocytosis: The effect of size of a particulate substrate on its mode of capture by rat peritoneal macrophages cultured in vitro
54. Size of IgG-opsonized particles determines macrophage response during internalization
55. Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages
56. In vivo cross-priming of MHC class I-restricted antigens requires the TAP transporter
57. Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules
58. Saponin and other haemolysins (vitamin A, aliphatic amines, polyene antibiotics) as adjuvants for SRBC in the mouse: Evidence for a role for cholesterol-binding in saponin adjuvanticity
59. Cytotoxic T lymphocyte response and viral load in hepatitis C virus infection
60. T-lymphocyte response to hepatitis C virus in different clinical courses of infection
61. + T lymphocytes from cancer patients are required for optimal induction of cytotoxic T cells against the autologous tumor
62. + CTL tumor immunosurveillance and regulation of tumor escape by CD4 T cells through an effect on quality of CTL